# ASX ANNOUNCEMENT
**August 28th, 2008**

---

## Sale of exploration interest

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce that it has reached agreement with Regis Resources Limited ("Regis") to dispose of its minority interest in the North Laverton Joint Venture (the "Joint Venture"), covering gold tenements in the Duketon central region, north of Laverton in Western Australia. Regis and its subsidiary currently hold the remaining interest in the Joint Venture.

This joint venture interest, which was acquired by the Company prior to the year 2000 when it operated in the exploration industry under the name of Duketon Goldfields Limited, represents the last exploration asset held by GTG.

Under the agreement, Regis will acquire GTG's entire interest in the Joint Venture which, at 30 June 2008, stood at 14.66%. In return for the sale, Regis will pay to GTG an amount of $100,000 in cash and issue to GTG 500,000 free-trading, fully paid ordinary shares in Regis.

As part of the sale, GTG will also have returned to it a performance bond which, at 30 June 2008, had a face value of $68,917. Further, under the agreement, GTG has been fully indemnified by Regis against any future rehabilitation liabilities which may arise from the exploration activities of the Joint Venture undertaken up until the date of sale. This indemnification will, in the financial year ending 30 June 2009, enable GTG to fully reverse the provision of $94,987 in respect of such liabilities which had been recorded in the Company's balance sheet at 30 June 2008.

---

FOR INFORMATION REGARDING THIS ANNOUNCEMENT PLEASE CONTACT

Michael B. Ohanessian
Chief Executive Officer

Genetic Technologies Limited (ABN 17 009 212 328)
Phone: +61 3 8412 7000